Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
Subscribe To Our Newsletter & Stay Updated